| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The prognosis of patients with high-risk neuroblastoma is extremely poor with a 5-year survival of 40%. Approximately 70% respond to chemotherapy but half of these patients experience recurrence. Once the tumor relapses, it gains chemoresistance and the outcome of relapsed patients is dismal. We hypothesized that tumors at diagnosis and recurrent tumors have different biological features based on different genomic and epigenetic rearrangements. We thus conducted a whole exome sequence for the tumors at diagnosis and tumors at recurrence in the identical patient. In one case, we found a novel somatic mutation in the recurrent tumor in a molecule that is not involved in the Ras-MAP kinase cascade, in which molecules has previously shown to be frequently mutated in recurrent tumors. This finding suggests that a somatic mutation in a molecule distinct from the Ras-MAPK cascade could also trigger relapse and chemoresistance in neuroblastoma.
|
